Sheffield Teaching Hospitals NHS Foundation Trust
sth.nhs.ukTotal trials
209
Active
22
Phase 3
6
Total enrollment
22,354
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Selexipag | — | — | — | — | — | 1 | |
| Riociguat | — | — | — | — | — | 1 | |
| SGLT-2 inhibitor | — | — | — | — | — | 1 |
Next readouts
- 2026-01
- 2027-07-31
Top conditions
- Obesity8
- Osteoporosis7
- Coronary Artery Disease5
- Pulmonary Hypertension4
- Cystic Fibrosis4
- Multiple Sclerosis4
- Dyspepsia3
- Stroke3
Frequently asked questions about Sheffield Teaching Hospitals NHS Foundation Trust
- How many clinical trials does Sheffield Teaching Hospitals NHS Foundation Trust have on ClinicalTrials.gov?
- Sheffield Teaching Hospitals NHS Foundation Trust is listed as the lead sponsor on 209 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sheffield Teaching Hospitals NHS Foundation Trust's trials are in Phase 3?
- 6 of Sheffield Teaching Hospitals NHS Foundation Trust's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Sheffield Teaching Hospitals NHS Foundation Trust focus on?
- Sheffield Teaching Hospitals NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Obesity, Osteoporosis, Coronary Artery Disease, Pulmonary Hypertension, Cystic Fibrosis.
- When are Sheffield Teaching Hospitals NHS Foundation Trust's next clinical trial readouts?
- Sheffield Teaching Hospitals NHS Foundation Trust has 2 upcoming primary-completion readouts tracked here; the soonest is “Pulmonary Hypertension: Intensification and Personalisation of Combination Rx”, expected around 2026-01.